drugset / Trial / NCT06978621

Immunogenicity and Safety of I-HAV in Healthy Thai Children and Adolescents Lacking Protective Antibody After L-HAV

NCT06978621

NaSingle-groupOpen-labelPrevention

Summary

Hepatitis A virus (HAV) remains a common infection in Thai children. Two HAV vaccines are available: inactivated vaccine (I-HAV, 2 doses) and live-attenuated vaccine (L-HAV, single dose), but neither is included in Thailand's national immunization program. Our previous randomized, active-controlled, open-label, non-inferiority trial trial found that some participants remained seronegative after one L-HAV dose (anti-HAV IgG \<1 S/CO) (preliminary data). This study aims to evaluate the immunogenicity and safety of an additional dose of I-HAV in healthy Thai children and adolescents who did not develop protective antibody levels after a single dose of L-HAV.

Timeline

Start
2025-05-25
Primary completion
2025-06-22
Completion
2026-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Inactivated hepatitis A vaccine Vaccine 0.5 ml Intramuscular
Subject Inactivated hepatitis A vaccine Vaccine 1 ml Intramuscular